Gordon T. Cook

St. James University Hospital
United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 199 publications

Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data.

Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data.

Journal: BMJ open

Published: May 11, 2026

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

Journal: American journal of hematology

Published: April 09, 2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Journal: Leukemia

Published: February 18, 2026

Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.

Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.

Journal: Blood advances

Published: December 05, 2025

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Journal: Blood advances

Published: December 05, 2025

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: December 03, 2025

Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.

Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.

Journal: British journal of haematology

Published: October 02, 2025

Advance care planning in haematological malignancies: A qualitative exploratory analysis of the facilitators and barriers to implementing advance care planning in practice.

Advance care planning in haematological malignancies: A qualitative exploratory analysis of the facilitators and barriers to implementing advance care planning in practice.

Journal: Palliative & supportive care

Published: September 26, 2025

Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.

Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.

Journal: Haematologica

Published: August 24, 2025

COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network.

COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network.

Journal: British journal of haematology

Published: July 17, 2025

Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis.

Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis.

Journal: European journal of haematology

Published: July 14, 2025

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.

Journal: HemaSphere

Published: June 22, 2025

Showing 1-12 of 199

Last Updated: 09/26/2026